CR20170345A - Derivados de 4h-pirrol[3,2-c]piridin-4-ona - Google Patents

Derivados de 4h-pirrol[3,2-c]piridin-4-ona

Info

Publication number
CR20170345A
CR20170345A CR20170345A CR20170345A CR20170345A CR 20170345 A CR20170345 A CR 20170345A CR 20170345 A CR20170345 A CR 20170345A CR 20170345 A CR20170345 A CR 20170345A CR 20170345 A CR20170345 A CR 20170345A
Authority
CR
Costa Rica
Prior art keywords
pirrol
piridin
ona
derivatives
drugs
Prior art date
Application number
CR20170345A
Other languages
English (en)
Inventor
Klar Ulrich Dr
René Tempel
Schulze Volker Dr
Siemeister Gerhard Dr
Lienau Philip Dr
Hans Briem Dr
Graham Keith Dr
Bálint Jozsef Dr
Original Assignee
Bayer Pharma Aktiengesellchaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellchaft filed Critical Bayer Pharma Aktiengesellchaft
Publication of CR20170345A publication Critical patent/CR20170345A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de fórmula (I). procesos para su producción y su uso como fármacos.
CR20170345A 2015-01-28 2016-01-25 Derivados de 4h-pirrol[3,2-c]piridin-4-ona CR20170345A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15152944 2015-01-28
EP15200407 2015-12-16
PCT/EP2016/051432 WO2016120196A1 (en) 2015-01-28 2016-01-25 4h-pyrrolo[3,2-c]pyridin-4-one derivatives

Publications (1)

Publication Number Publication Date
CR20170345A true CR20170345A (es) 2017-09-29

Family

ID=55236350

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170345A CR20170345A (es) 2015-01-28 2016-01-25 Derivados de 4h-pirrol[3,2-c]piridin-4-ona

Country Status (30)

Country Link
US (1) US10428063B2 (es)
EP (1) EP3250567B1 (es)
JP (1) JP6704398B2 (es)
KR (1) KR102544847B1 (es)
CN (1) CN107406417B (es)
AU (1) AU2016212230B2 (es)
BR (1) BR112017016193B1 (es)
CA (1) CA2974853C (es)
CL (1) CL2017001930A1 (es)
CO (1) CO2017007663A2 (es)
CR (1) CR20170345A (es)
CU (1) CU20170094A7 (es)
DO (1) DOP2017000176A (es)
EA (1) EA032530B1 (es)
EC (1) ECSP17048527A (es)
IL (1) IL253284B (es)
JO (1) JO3706B1 (es)
MX (1) MX380239B (es)
MY (1) MY182181A (es)
NI (1) NI201700096A (es)
PE (1) PE20171240A1 (es)
PH (1) PH12017501340A1 (es)
SG (1) SG11201705908VA (es)
SV (1) SV2017005487A (es)
TN (1) TN2017000329A1 (es)
TW (1) TWI699359B (es)
UA (1) UA122221C2 (es)
UY (1) UY36544A (es)
WO (1) WO2016120196A1 (es)
ZA (1) ZA201705802B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2708211T3 (es) 2014-06-17 2019-04-09 Bayer Pharma AG 3-amino-1,5,6,7-tetrahidro-4H-indol-4-onas
US10227299B2 (en) 2015-06-17 2019-03-12 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones
CA2994596A1 (en) 2015-08-05 2017-02-09 Bayer Pharma Aktiengesellschaft 1h-pyrrol-3-amines
ES2828431T3 (es) 2015-12-16 2021-05-26 Loxo Oncology Inc Compuestos útiles como inhibidores de cinasa
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
KR102440006B1 (ko) 2017-08-23 2022-09-05 현대모비스 주식회사 차량용 브레이크의 캘리퍼 장치
CA3079786A1 (en) 2017-10-24 2019-05-02 The Broad Institute, Inc. 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
PE20211655A1 (es) 2018-10-31 2021-08-24 Gilead Sciences Inc Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
CA3168211A1 (en) 2019-01-18 2020-07-23 Voronoi Co., Ltd. Pyrrolopyridine derivative and use thereof for preventing or treating protein kinase related disease
CA3128946A1 (en) 2019-02-07 2020-08-13 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors
US20240307362A1 (en) 2019-04-24 2024-09-19 Bayer Aktiengesellschaft 4H-PYRROLO[3,2-c]PYRIDIN-4-ONE COMPOUNDS
GEP20247648B (en) * 2019-04-24 2024-07-25 Bayer Ag 4h-pyrrolo[3,2-c]pyridin-4-one compounds
EP3958865B1 (en) 2019-04-24 2025-12-10 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
EP4509122A3 (en) 2020-07-29 2025-04-23 Bayer Aktiengesellschaft Substituted heterocyclic compounds and therapeutic uses thereof
US20230365554A1 (en) 2020-07-29 2023-11-16 The Broad Institute, Inc. Substituted pyrrolo-pyridinone derivatives and therapeutic uses thereof
EP4188928B1 (en) 2020-07-29 2024-07-24 Bayer Aktiengesellschaft Substituted 1 h-pyrrolo[3,2-b]pyridin compounds and methods of use thereof
US20230322767A1 (en) 2020-07-29 2023-10-12 Bayer Aktiengesellschaft Aryl substituted pyrrolo-pyridinones and therapeutic uses thereof
CN115836070B (zh) * 2020-08-10 2024-08-09 上海和誉生物医药科技有限公司 作为egfr抑制剂的稠环化合物及其制备方法和应用
CN116997549A (zh) * 2020-09-23 2023-11-03 蝎子疗法股份有限公司 用于治疗癌症的吡咯并[3,2-c]吡啶-4-酮衍生物
CA3196712A1 (en) 2020-09-23 2022-03-31 Scorpion Therapeutics, Inc. Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer
WO2022072645A2 (en) * 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
CN116981667A (zh) * 2020-10-09 2023-10-31 蝎子疗法股份有限公司 用于癌症治疗的egfr和/或her2的杂环抑制剂
TW202227063A (zh) * 2020-10-09 2022-07-16 美商史考皮恩治療有限公司 治療癌症之方法
WO2022094271A1 (en) * 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) * 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
KR20220081631A (ko) 2020-12-09 2022-06-16 보로노이 주식회사 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
EP4469457A4 (en) * 2022-01-27 2026-01-21 Broad Inst Inc CSNK1 SUBSTITUTE HETEROCYCLIC INHIBITORS
EP4499635A1 (en) 2022-03-24 2025-02-05 Scorpion Therapeutics, Inc. Methods of synthesizing egfr inhibitors
WO2024182715A1 (en) * 2023-03-02 2024-09-06 Schrödinger, Inc. Heterocyclics as egfr inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
AR056560A1 (es) 2005-10-06 2007-10-10 Astrazeneca Ab Pirrolopiridinonas como moduladores cb1
US20070142414A1 (en) 2005-12-16 2007-06-21 Pharmacia Italia S.P.A. N-substituted pyrrolopyridinones active as kinase inhibitors
EP2203442B1 (en) 2007-09-28 2012-06-20 Nerviano Medical Sciences S.r.l. Substituted pyrrolo-pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
JP5386508B2 (ja) * 2008-01-22 2014-01-15 ヴァーナリス アールアンドディー リミテッド インドリル−ピリドン誘導体類
WO2010145998A1 (en) 2009-06-15 2010-12-23 Nerviano Medical Sciences S.R.L. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
US9181258B2 (en) * 2011-10-07 2015-11-10 Nerviano Medical Sciences S.R.L. Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors
CA2846066A1 (en) 2011-10-28 2013-05-02 Chong Kun Dang Pharmaceutical Corp. Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof
ES2638144T3 (es) 2011-12-21 2017-10-18 Bayer Intellectual Property Gmbh Bencilpirazoles sustituidos
HK1207861A1 (en) 2012-05-11 2016-02-12 Bayer Pharma Aktiengesellschaft Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer
WO2014022752A1 (en) 2012-08-03 2014-02-06 Amgen Inc. Macrocycles as pim inhibitors
ES2755772T3 (es) 2012-11-07 2020-04-23 Nerviano Medical Sciences Srl Pirimidinil y piridinilpirrolopiridinonas sustituidas, proceso para su preparación y su uso como inhibidores de cinasas
US20160046610A1 (en) * 2013-03-21 2016-02-18 Bayer Pharma Aktiengesellschaft 3-heteroaryl substituted indazoles
HK1223350A1 (zh) 2013-03-21 2017-07-28 Bayer Pharma Aktiengesellschaft 杂芳基取代的吲唑
EP3010911A1 (en) 2013-06-21 2016-04-27 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
WO2014202583A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
CN105452237A (zh) 2013-06-21 2016-03-30 拜耳制药股份公司 杂芳基取代的吡唑
EP3010904A1 (en) 2013-06-21 2016-04-27 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
AR097325A1 (es) 2013-08-13 2016-03-09 Gruenenthal Gmbh Pirroles anillados
ES2708211T3 (es) * 2014-06-17 2019-04-09 Bayer Pharma AG 3-amino-1,5,6,7-tetrahidro-4H-indol-4-onas
US10227299B2 (en) 2015-06-17 2019-03-12 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones
CA2994596A1 (en) 2015-08-05 2017-02-09 Bayer Pharma Aktiengesellschaft 1h-pyrrol-3-amines
JP2019504826A (ja) 2015-12-16 2019-02-21 バイエル ファーマ アクチエンゲゼルシャフト ヘテロ−１，５，６，７−テトラヒドロ−４ｈ−インドール−４−オン類

Also Published As

Publication number Publication date
AU2016212230A1 (en) 2017-07-20
KR20170106452A (ko) 2017-09-20
CA2974853C (en) 2023-02-21
KR102544847B1 (ko) 2023-06-16
US10428063B2 (en) 2019-10-01
JP2018503648A (ja) 2018-02-08
WO2016120196A1 (en) 2016-08-04
MY182181A (en) 2021-01-18
EA201791692A1 (ru) 2018-01-31
UY36544A (es) 2016-08-31
NI201700096A (es) 2017-10-24
EP3250567A1 (en) 2017-12-06
BR112017016193A2 (pt) 2018-04-17
PE20171240A1 (es) 2017-08-24
UA122221C2 (uk) 2020-10-12
CA2974853A1 (en) 2016-08-04
MX380239B (es) 2025-03-12
CL2017001930A1 (es) 2018-03-09
CN107406417A (zh) 2017-11-28
MX2017009831A (es) 2017-11-02
SG11201705908VA (en) 2017-08-30
JP6704398B2 (ja) 2020-06-03
IL253284B (en) 2020-08-31
HK1244804A1 (zh) 2018-08-17
EP3250567B1 (en) 2019-10-30
CO2017007663A2 (es) 2017-10-10
TN2017000329A1 (en) 2019-01-16
SV2017005487A (es) 2019-01-17
AU2016212230B2 (en) 2019-09-19
JO3706B1 (ar) 2021-01-31
US20180016272A1 (en) 2018-01-18
TW201639828A (zh) 2016-11-16
ZA201705802B (en) 2019-07-31
CU20170094A7 (es) 2017-12-08
IL253284A0 (en) 2017-09-28
EA032530B1 (ru) 2019-06-28
BR112017016193B1 (pt) 2023-02-23
PH12017501340A1 (en) 2017-12-18
DOP2017000176A (es) 2017-08-31
CN107406417B (zh) 2020-06-09
ECSP17048527A (es) 2017-10-31
TWI699359B (zh) 2020-07-21

Similar Documents

Publication Publication Date Title
DOP2017000176A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
ECSP20021132A (es) Enantiómeros de tiazoles sustituidos compuestos antivirales
UY35500A (es) Indazoles sustituidos con heteroarilo
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
CL2016001895A1 (es) Compuestos
UY35467A (es) Compuestos orgánicos
MX373247B (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina.
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
UY34725A (es) Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos.
UY35499A (es) Indazoles sustituidos con diaminoheteroarilo
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
UY35610A (es) Derivados de prodroga de triazolpiridinas sustituidas
UY35665A (es) ?compuestos de carboxamida, proceso de preparación y su uso como nematicidas?.
MX373441B (es) Derivados de indol-urea glucopiranosil-sustituido y su uso como inhibidores sglt.
GT201500116A (es) Mètodo para preparar derivados de feniloximetil-nitro-imidazol y su uso del mismo